Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4777)	7/7/1998 2:25:00 AM
From: George T. Santamaria	Respond to of 6136

To whom it may concern -- Do large retail Brokerages work very hard to make their competitors look bad? Note that the AGPH's sails started luffing just prior to March '97 when PW's main AGPH proponent left the company. There hasn't been a steady wind in their sails since. I've been thinking that MS has been out to make PW look bad to their clientele. PW must have egg on their face and scars on their behind with their long-standing $65-70 price tag for AGPH. It's easy to see how MS could hire away a respected analyst from PW and then use him/her and their market clout to force the price of a key issue down and then, at the right moment, put their clientele into the stock and push the price up - by whatever means possible. MS looks good, PW looks bad. This story was easy to imagine before today's free-fall. It's real hard to believe this story and ride it out now.